DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis

RIS ID

95774

Publication Details

Mossner, R., Schuhmacher, A., Wagner, M., Quednow, B. B., Frommann, I., Kuhn, K., Schwab, S. G., Rietschel, M., Falkai, P., Wolwer, W., Ruhrmann, S., Bechdolf, A., Gaebel, W., Klosterkotter, J. & Maier, W. (2010). DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. European Archives of Psychiatry and Clinical Neuroscience: official organ of the German society for biological psychiatry, 260 (3), 209-215.

Abstract

The genetic factors determining the progression of prodromal syndromes to first episode schizophrenia have remained enigmatic to date. In a unique prospective multicentre trial, we assessed whether variants at the d-amino acid oxidase activator (DAOA)/G72 locus influence progression to psychosis. Young subjects with a prodromal syndrome were observed prospectively for up to 2 years to assess the incidence of progression to schizophrenia or first episode psychosis. Of the 82 probands with a prodromal syndrome, 21 probands experienced progression to psychosis within the observation period. Assessment of nine common variants in the DAOA/G72 locus yielded two variants with the predictive value for symptom progression: all four probands with the rs1341402 CC genotype developed psychosis compared with 17 out of 78 probands with the TT or CT genotypes (χ2 = 12.348; df = 2; p = 0.002). The relative risk for progression to psychosis was significantly increased in the CC genotype: RR = 4.588 (95% CI = 2.175-4.588). Similarly, for rs778294, 50% of probands with the AA genotype, but only 22% of probands with a GG or GA genotype progressed to psychosis (χ2 = 7.027; df = 2; p = 0.030). Moreover, haplotype analysis revealed a susceptibility haplotype for progression to psychosis. This is one of the first studies to identify a specific genetic factor for the progression of prodromal syndromes to schizophrenia, and further underscores the importance of the DAOA/G72 gene for schizophrenia.

Please refer to publisher version or contact your library.

Share

COinS
 

Link to publisher version (DOI)

http://dx.doi.org/10.1007/s00406-009-0044-y